In the healing of acute ischemic stroke, a new pooled analysis of randomized trials of tissue plasminogen activator (tPA), has now expanded to consist of more trials. The research has established benefit of treatment to 4.5 hours, and has, for the first time showed that threat may outweigh benefit after that time.

With a total number of eight collective studies, the data has been fetched together from the current European Cooperative Acute Stroke Study 3 (ECASS 3) and the Echoplanar Imaging Thrombolysis Evaluation Trial (EPITHET).

Treatment with thrombolysis awaiting 4.5 hours from stroke onset boosts the chance of favorable outcome, as updated by an analysis. Where, parenchymal hemorrhage rates were autonomous of time to treatment; it was the mortality that augmented with thrombolytic therapy after 4.5 hours, signifying that other mechanisms of mortality may be involved.

"However, across the time window studied, our analysis showed that the greatest benefit comes from earlier treatment, since net benefit is diminishing and is undetectable in our sample beyond 4.5 [hours]", writes researchers, with lead study author Kennedy R. Lees, FRCP, from the Western Infirmary at the University of Glasgow, Scotland.

An experiment discovered that the odds of a favorable outcome amplified as the time from stroke onset to treatment dwindled, with no further benefit seen after 270 minutes (4.5 hours).